HAE treatment switch linked to fewer medical visits, data show

Patients on Orladeyo saw doctors less, had fewer emergency visits

Written by Andrea Lobo |

An image shows a woman giving a presentation.

Biocryst presented new data on Orladeyo. (Image by iStock)

People with hereditary angioedema (HAE) who switched to Orladeyo (berotralstat) from another preventive treatment experienced fewer disease-related medical visits, real-world data show.

An analysis in the U.S. found a 30% reduction in overall HAE-related healthcare visits per patient-year, while a separate study found fewer hospitalizations and emergency department visits among patients who started Orladeyo or other long-term preventive therapies.

Biocryst Pharmaceuticals, the company that markets Orladeyo, was scheduled to present the results during the American College of Allergy, Asthma & Immunology (ACAAI) 2026 annual scientific meeting, held Nov. 12-16 in Phoenix.

“These real-world studies add to our understanding of healthcare resource utilization among patients with HAE who either initiate Orladeyo or switch from another long-term prophylactic therapy,” Sandra Christiansen, MD, professor at the University of California San Diego, said in a company press release.

HAE is characterized by recurrent episodes of swelling in the deeper layers of the skin and mucous membranes. These attacks are driven by excessive production of bradykinin, a signaling molecule that causes fluid to leak from blood vessels into surrounding tissues. Swelling can affect the face, abdomen, hands, and feet, and can become life-threatening when it affects the throat.

Recommended Reading
Banner for

Better understanding the HAE attack triggers in our lives

Once-daily treatment aimed at easing swelling attacks

Orladeyo is approved in the U.S. and several other countries as a long-term prophylactic treatment, meaning it is used to prevent and reduce the burden of HAE attacks, for patients aged 2 and older. Taken orally once daily, it blocks plasma kallikrein, an enzyme involved in bradykinin production, helping reduce the frequency and burden of swelling attacks.

The first study, presented in a poster titled “Reductions in Healthcare Utilization Among Individuals with HAE Who Switched to Berotralstat from Another Prophylaxis,” retrospectively analyzed U.S. administrative insurance claims linked to data from BioCryst’s specialty pharmacy.

It involved 78 people with HAE who switched from another long-term preventive therapy to Orladeyo. Participants’ mean age was 41.8, and 78.2% were women. The most common previous treatments were Takhzyro (lanadelumab, 42%), human C1-esterase inhibitors – Haegarda (26%) or Cinryze (5%) – and danazol (19%).

Before switching, patients had a mean of 6.12 HAE-related medical visits per patient-year, including 5.86 outpatient/emergency department visits. After switching to Orladeyo, the corresponding rates fell to 4.06 and 3.93, respectively, representing reductions of more than 30%. A patient-year is a measure of healthcare use that accounts for both the number of patients and the time they were followed.

HAE-related hospitalizations also decreased, from 0.27 to 0.12 per patient-year, but this reduction was not statistically significant.

A second retrospective study examined people with HAE who had not previously received long-term preventive treatment. Its findings were presented in a poster titled “Hospitalization and Emergency Department Reductions After Initiating Berotralstat, Lanadelumab, or Subcutaneous Plasma-Derived C1-Inhibitor for Hereditary Angioedema.”

The study involved 459 participants, 128 who started Orladeyo, 236 who were on Takhzyro, and 95 who received human-derived C1 inhibitors.

All three groups experienced statistically significant reductions in emergency department visits, with fewer hospitalizations observed as well. Among those who started Orladeyo, all-cause and HAE-related hospitalizations decreased by 53%, while HAE-related emergency department visits fell by 61%. Emergency department visits due to any cause decreased by 41%.

“Taken together, these findings support Orladeyo’s clinical and economic benefits as a long-term prophylactic therapy for HAE,” Christiansen said.

Another presentation featured new data from the ongoing Phase 3 APeX-P trial (NCT05453968) showing that adjusting Orladeyo doses according to body weight in children with HAE was well tolerated.

The company also shared interim results from the ALPHA-SOLAR Phase 2 extension study (NCT06007677), which is evaluating the long-term safety and efficacy of navenibart, an experimental antibody-based therapy designed to block kallikrein and prevent attacks, in patients with HAE who completed the prior Phase 1/2 ALPHA-STAR study (NCT05695248). Consistent with earlier findings, navenibart continued to be well tolerated, reduced monthly swelling attack rates for up to two years, and improved patients’ quality of life.

Leave a comment

Fill in the required fields to post. Your email address will not be published.

Comments are moderated. Once approved, your comment and username will be publicly visible. Please avoid sharing personal health information or other sensitive details.